Intellectual Property

Ablynx has a strong and broad patent portfolio of more than 500 pending and granted patents in about 100 families which covers various aspects of the discovery, generation, optimisation, formatting, manufacture, administration, formulation and clinical use of Nanobodies, as well as covering its clinical development programmes and product candidates.

This patent portfolio, combined with the extensive experience and expertise that Ablynx has established as the first company to discover and develop Nanobodies and to achieve clinical proof-of-concept for multiple clinical programmes, puts Ablynx in a unique position to exploit the Nanobody platform in the field of therapy and diagnosis.

Ablynx is also the holder worldwide of the trademarks Ablynx®, Nanobody® and Nanoclone®.

For more information on Ablynx's IP portfolio, please contact